GSK's new vaccine, Penmenvy, targeting five meningococcal serogroups, has received FDA approval for individuals aged 10-25. The vaccine combines antigens from Bexsero and Menveo, with studies confirming its safety profile.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay